Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing
Weng Y., Ishino T., Sievers A., Talukdar S., Chabot JR., Tam A.
Prospective Study on Systemic / IV, published in Sci Rep (2018) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Sci Rep (2018)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 29523796
- PMCID
- PMC5844872
- DOI
- 10.1038/s41598-018-22456-w
- Citations
- 25
Abstract (original English)
Pharmacological administration of FGF21 analogues has shown robust body weight reduction and lipid profile improvement in both dysmetabolic animal models and metabolic disease patients. Here we report the design, optimization, and characterization of a long acting glyco-variant of FGF21. Using a combination of N-glycan engineering for enhanced protease resistance and improved solubility, Fc fusion for further half-life extension, and a single point mutation for improving manufacturability in Chinese Hamster Ovary cells, we created a novel FGF21 analogue, Fc-FGF21[R19V][N171] or PF-06645849, with substantially improved solubility and stability profile that is compatible with subcutaneous (SC) administration. In particular, it showed a low systemic clearance (0.243 mL/hr/kg) and long terminal half-life (~200 hours for intact protein) in cynomolgus monkeys that approaches those of monoclonal antibodies. Furthermore, the superior PK properties translated into robust improvement in glucose tolerance and the effects lasted 14 days post single SC dose in ob/ob mice. PF-06645849 also caused greater body weight loss in DIO mice at lower and less frequent SC doses, compared to previous FGF21 analogue PF-05231023. In summary, the overall PK/PD and pharmaceutical profile of PF-06645849 offers great potential for development as weekly to twice-monthly SC administered therapeutic for chronic
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
The suitability of mesenchymal stem cells for treating immune-mediated inflammatory skin diseases: a systematic review
Systematic Review with a reported sample of 609 on Hair Loss, Immune Modulation, Autoimmune Research, published in Dermatol Reports (2026) — summary generated from the PubMed abstract.
- 2026
- n = 609
Dermatol Reports - Level ASystematic ReviewEurope PMC
The Influence of GLP-1 Agonists on Human Mesenchymal Stem Cells: A Systematic Review
Systematic Review on Type 2 Diabetes, published in Stem Cell Rev Rep (2026) — summary generated from the PubMed abstract.
- 2026
Stem Cell Rev Rep2 citations - Level AMeta-analysisEurope PMC
Single cell transcriptomics of human weight loss links adipocyte NPY1R to control of lipolysis
Meta-analysis on Systemic / IV, published in Mol Metab (2026) — summary generated from the PubMed abstract.
- 2026
Mol Metab - Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level ASystematic ReviewPubMed
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.
Systematic Review on Neuroinflammation, published in Tissue Eng Regen Med (2026) — summary generated from the PubMed abstract.
- 2026
Tissue Eng Regen Med - Level ASystematic ReviewEurope PMC
Applications of Exosomes in Female Medicine: A Systematic Review of Molecular Biology, Diagnostic and Therapeutic Perspectives
Systematic Review on Face & Skin, Systemic / IV, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci2 citations